Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 18Magnetic Resonance Spectroscopy 9Biopsy 9X-Rays 5Cyclophosphamide 5venetoclax 4fludarabine 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Dexamethasone 4Calcium Dobesilate 4carfilzomib 3Hyaluronoglucosaminidase 3sargramostim 2pomalidomide 2decitabine and cedazuridine drug combination 2daratumumab 2balstilimab 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Melphalan 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytarabine 2Colony-Stimulating Factors 2Busulfan 2trastuzumab deruxtecan 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × Glutamate Carboxypeptidase II × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡